Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Yizhen Guo"'
Autor:
Trang T. Vu, Kyeongmin Kim, Millennium Manna, Justin Thomas, Bryan C. Remaily, Emma J. Montgomery, Travis Costa, Lauren Granchie, Zhiliang Xie, Yizhen Guo, Min Chen, Alyssa Marie M. Castillo, Samuel K. Kulp, Xiaokui Mo, Sridhar Nimmagadda, Paul Gregorevic, Dwight H. Owen, Latha P. Ganesan, Thomas A. Mace, Christopher C. Coss, Mitch A. Phelps
Publikováno v:
Pharmacological Research, Vol 199, Iss , Pp 107048- (2024)
High baseline clearance of immune checkpoint inhibitors (ICIs), independent of dose or systemic exposure, is associated with cachexia and poor outcomes in cancer patients. Mechanisms linking ICI clearance, cachexia and ICI therapy failure are unknown
Externí odkaz:
https://doaj.org/article/2e67e650671f4d189b77c2eafc481db4
Autor:
Justin Thomas, Thomas Mace, Mitch Phelps, Trang Vu, Dwight Owen, Bryan Remaily, Kyeongmin Kim, Zhiliang Xie, Samuel Kulp, Hannah Lathrop, Camille Stanton, Millenium Manna, Lauren Granchie, Yizhen Guo, Latha Ganesan, Chris C Coss
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/4d1558699f3b49b4a0d108a8805397dc
Autor:
Alyssa Marie M. Castillo, Trang T. Vu, Sophia G. Liva, Min Chen, Zhiliang Xie, Justin Thomas, Bryan Remaily, Yizhen Guo, Uma L. Subrayan, Travis Costa, Timothy H. Helms, Donald J. Irby, Kyeongmin Kim, Dwight H. Owen, Samuel K. Kulp, Thomas A. Mace, Mitch A. Phelps, Christopher C. Coss
Publikováno v:
JCSM Rapid Communications, Vol 4, Iss 2, Pp 232-244 (2021)
Abstract Background Monoclonal antibody (mAb) immune checkpoint inhibitor (ICI) therapies have dramatically impacted oncology this past decade. However, only about one‐third of patients respond to treatment, and biomarkers to predict responders are
Externí odkaz:
https://doaj.org/article/db94475297f14a02937ba2decc4f78d7
Autor:
Chao Hong, Jianming Liang, Jiaxuan Xia, Ying Zhu, Yizhen Guo, Anni Wang, Chunyi Lu, Hongwei Ren, Chen Chen, Shiyi Li, Dan Wang, Huaxing Zhan, Jianxin Wang
Publikováno v:
Nano-Micro Letters, Vol 12, Iss 1, Pp 1-18 (2020)
Abstract Liposomes hold great potential in anti-cancer drug delivery and the targeting treatment of tumors. However, the clinical therapeutic efficacy of liposomes is still limited by the complexity of tumor microenvironment (TME) and the insufficien
Externí odkaz:
https://doaj.org/article/577d0151f2594238842338277967535c
Publikováno v:
Molecules, Vol 23, Iss 9, p 2113 (2018)
Background: Ginsenoside Rg5 has been proved to have a wide range of pharmacological activities. However, the in vitro and in vivo metabolism pathways of ginsenosides are still unclear, which impedes the understanding of their in vivo fate. In this pa
Externí odkaz:
https://doaj.org/article/2ba9555be7874f45ba426b3d610e33d7
Publikováno v:
Inventions, Vol 3, Iss 1, p 18 (2018)
In this study, multi-walled carbon nanotubes (MW-CNT) were successfully synthesized using a chemical vapor deposition-fluidized bed (CVD-FB), with 10% hydrogen and 90% argon by volume, and a reaction temperature between 750 and 850 °C in a specially
Externí odkaz:
https://doaj.org/article/a0252a7db26d436fa090a0a945a3045a
Autor:
Dylan L. Burroughs, Gwendolen Lorch, Yizhen Guo, Kasey Hill, Eric L. Schroeder, Lynette K. Cole, Mitch A. Phelps
Publikováno v:
Veterinary Dermatology. 34:222-234
Mycophenolate mofetil (MMF) is the prodrug of mycophenolic acid (MPA) which acts as an immunosuppressive agent. During the biotransformation of MMF to MPA, additional metabolites including MPA phenol glucuronide (MPAG), MPA acyl glucuronide (AcMPAG)
Autor:
Trang T. Vu, Kyeongmin Kim, Millennium Manna, Justin Thomas, Bryan Remaily, Emma J. Montgomery, Travis Costa, Lauren Granchie, Zhiliang Xie, Yizhen Guo, Min Chen, Alyssa Marie M. Castillo, Samuel K. Kulp, Xiaokui Mo, Sridhar Nimmagadda, paul gregorevic, Dwight H. Owen, Latha P. Ganesan, Thomas A. Mace, Christopher C. Coss, Mitch A. Phelps
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9935f7885e84c4fb99ccbd5a6769edb3
https://doi.org/10.2139/ssrn.4423641
https://doi.org/10.2139/ssrn.4423641
Publikováno v:
Chemico-Biological Interactions. 378:110467
Autor:
Thomas A. Mace, Samuel K. Kulp, Yizhen Guo, Sophia G. Liva, Trang Vu, Alyssa Marie M Castillo, Uma L Subrayan, Justin Thomas, Timothy H. Helms, Min Chen, Kyeongmin Kim, Zhiliang Xie, Christopher C. Coss, Travis Costa, Bryan Remaily, Mitch A. Phelps, Donald J. Irby, Dwight H. Owen
Publikováno v:
JCSM Rapid Communications, Vol 4, Iss 2, Pp 232-244 (2021)
Jcsm Rapid Communications
Jcsm Rapid Communications
Background Monoclonal antibody (mAb) immune checkpoint inhibitor (ICI) therapies have dramatically impacted oncology this past decade. However, only about one‐third of patients respond to treatment, and biomarkers to predict responders are lacking.